ELICIO THERAPEUTICS ELTX 深 沪
交易中 09-29 11:56:08 美东时间
10.8634
-0.137
-1.24%
华盛通- 最 高11.26
- 今 开11.26
- 成交量 1.17万股
- 最 低 10.8313
- 昨 收 11.00
- 总市值 1.77亿
- 52周最高 12.62
- 市盈率 静 --
- 换手率 0.07%
- 52周最低 4.05
- 委 比 -83.53%
- 总股本 1633.83万
- 历史最高 263.00
- 量 比 0.68
- 振 幅 3.90%
- 历史最低 2.96
- 每 手 1
- 风险率 2.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Elicio Therapeutics Announces Planned Initiation Of Investigator-Initiated Phase 1 Trial Of ELI-002 7P In Combination With Chemotherapy And Anti-PD1 Checkpoint Inhibitor In Borderline And Resectable PDAC
Study will evaluate ELI-002 7P in combination with chemotherapy and a checkpoint inhibitor ("CPI") in the neoadjuvant setting Trial is anticipated to begin enrolling in H1'2026 BOSTON, Sept. 29, 2025 (GLOBE
今天 20:19
Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma
Elicio Therapeutics plans to initiate a Phase 1 neoadjuvant study of ELI-002 7P, an investigational AMP cancer vaccine targeting KRAS-driven cancers, in combination with chemotherapy (mFOLFIRINOX) and an anti-PD-1 checkpoint inhibitor for pancreatic ductal adenocarcinoma (PDAC). The investigator-initiated trial, led by Dr. Kevin Soares of Memorial Sloan Kettering Cancer Center and funded by the Lustgarten Foundation, aims to enroll 20 patients ac...
今天 12:00
Elicio Therapeutics Reports Inducement Grants
Elicio Therapeutics granted 9,800 inducement stock options to two new employees on September 15, 2025, priced at $10.08 per share, vesting over four years. The company, focusing on novel immunotherapies for high-prevalence cancers, is advancing its lead program ELI-002, an off-the-shelf vaccine targeting KRAS mutations, with promising data from Phase 1 studies in pancreatic and colorectal cancers. Elicio plans to expand ELI-002 to other indicatio...
09-18 12:00
Elicio's ELI-002 Triggers mKRAS-Specific T Cell Responses In 99% Of Phase 2 AMPLIFY-7P Trial Patients
ELI-002 induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90) who were treated with the investigational vaccine immunotherapyRobust mKRAS-specific T cell responses were observed with an average
09-17 20:08
Elite Express Holding Inc. Announces Pricing of $15.2 Million Initial Public Offering
Elite Express Holding Inc. (ETS) announced the pricing of its initial public offering of 3,800,000 shares of Class A common stock at $4.00 per share, with total gross proceeds of approximately $15.2 million. The offering included an option for underwriters to purchase an additional 570,000 shares. ETS's shares will begin trading on the Nasdaq Capital Market under the ticker "ETS" on August 21, 2025, and the offering is expected to close on August...
08-20 23:53
美股牛股 | 迅雷绩后上演翻倍行情！投资影石创新浮盈超50亿；OpenDoor隔夜大涨19%
迅雷绩后上演翻倍行情！投资影石创新浮盈超50亿；OpenDoor隔夜大涨19%，此前获知名加密货币投资者买入>>
08-19 19:53
Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients
Elicio Therapeutics reported promising results from the Phase 1 AMPLIFY-201 study of ELI-002, a mutant KRAS (mKRAS)-targeting vaccine, in patients with pancreatic and colorectal cancers. The study showed a significant improvement in overall survival (OS) from 16.33 to 28.94 months, alongside a 77% reduction in the risk of death and an 88% reduction in the risk of relapse. ELI-002 induced robust T cell responses, particularly CD4+ and CD8+ mKRAS-s...
08-12 12:00
Elicio Therapeutics Q2 EPS $(0.66) Misses $(0.65) Estimate
Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.66) per share which missed the analyst consensus estimate of $(0.65) by 1.54 percent. This is a 3.13 percent decrease over losses of $(0.64) per share
08-08 04:37
Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
<p>Elicio Therapeutics reported positive updates on its Phase 2 study for pancreatic cancer, securing $10 million in financing, and detailed its financial results. The IDMC recommended continuing the ELI-002 7P trial without modifications, with final data expected in Q4 2025.</p>
08-07 20:30
Elicio's Pancreatic Cancer Vaccine Trial Clears Key Review, Moves Ahead Without Changes
Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company"))), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that following the
08-05 19:11
